NCT00271622 The Neurodevelopmental and Behavioral Phenotyping Screening Protocol
| NCT ID | NCT00271622 |
| Status | Recruiting |
| Phase | — |
| Sponsor | National Institute of Mental Health (NIMH) |
| Condition | Neurologic Disorders |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2006-02-27 |
| Primary Completion | — |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2006-02-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this protocol is to allow for the careful evaluation of healthy volunteers and individuals with risk for psychiatric disorders or neurodevelopmental disorders, such as autism spectrum disorder for specific protocols at NIH.
Eligibility Criteria
* INCLUSION CRITERIA: * Subjects must be at least 6 weeks of age. * Subjects or their parents must be competent to comprehend the purpose of the screening process and to provide written informed consent. Parents/guardians will sign the consent form, and both minors and adults (depending on results of capacity assessment) will be asked to assent only if it is determined that they understand their role in the study. * Subjects must be willing to undergo an evaluation which may include a psychiatric interview; and medical, neurological, and laboratory examinations (as appropriate, such as renal and liver function tests, serum electrolytes, urinalysis, blood levels of psychotropic drugs, and urine drug screen for the presence of psychoactive drugs and drugs of abuse, as determined on a subject-to-subject basis). EXCLUSION CRITERIA: -Lack of appropriate consent: For minor patients, consent must be obtained from all legal guardians/caretakers, including both parents in separated or divorced families where there is shared legal custody of the child. In such cases, both parents must consent to the child s participation in this protocol.
Contact & Investigator
Genalynne C Mooneyham, M.D.
PRINCIPAL INVESTIGATOR
National Institute of Mental Health (NIMH)
Frequently Asked Questions
Who can join the NCT00271622 clinical trial?
This trial is open to participants of all sexes, aged 6 Weeks or older, studying Neurologic Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00271622 currently recruiting?
Yes, NCT00271622 is actively recruiting participants. Contact the research team at pekarm@mail.nih.gov for enrollment information.
Where is the NCT00271622 trial being conducted?
This trial is being conducted at Bethesda, United States.
Who is sponsoring the NCT00271622 clinical trial?
NCT00271622 is sponsored by National Institute of Mental Health (NIMH). The principal investigator is Genalynne C Mooneyham, M.D. at National Institute of Mental Health (NIMH). The trial plans to enroll 5,000 participants.